Last reviewed · How we verify
10 day concomitant regimen
10 day concomitant regimen is a Small molecule drug developed by Alexandra Hospital, Athens, Greece. It is currently FDA-approved. Also known as: Amoxicillin 1gr bid from day 1 to day 10, Clarithromycin 500mg bid from day 1 to day 10, Metronidazole 500mg bid from day 1 to day 10, Esomeprazole 40mg bid from day 1 to day 10.
At a glance
| Generic name | 10 day concomitant regimen |
|---|---|
| Also known as | Amoxicillin 1gr bid from day 1 to day 10, Clarithromycin 500mg bid from day 1 to day 10, Metronidazole 500mg bid from day 1 to day 10, Esomeprazole 40mg bid from day 1 to day 10 |
| Sponsor | Alexandra Hospital, Athens, Greece |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (PHASE2)
- VAC Regimen for AML Patients Who Failed to Response to VA Regimen (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet (PHASE1)
- Effects of BREA and MFT Expansion Appliances on Upper Airway Dimensions (NA)
- STOP-HER2: Stopping Trastuzumab in HER2+ MBC (PHASE2)
- Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 10 day concomitant regimen CI brief — competitive landscape report
- 10 day concomitant regimen updates RSS · CI watch RSS
- Alexandra Hospital, Athens, Greece portfolio CI
Frequently asked questions about 10 day concomitant regimen
What is 10 day concomitant regimen?
Who makes 10 day concomitant regimen?
Is 10 day concomitant regimen also known as anything else?
What development phase is 10 day concomitant regimen in?
Related
- Manufacturer: Alexandra Hospital, Athens, Greece — full pipeline
- Also known as: Amoxicillin 1gr bid from day 1 to day 10, Clarithromycin 500mg bid from day 1 to day 10, Metronidazole 500mg bid from day 1 to day 10, Esomeprazole 40mg bid from day 1 to day 10
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing